Targeting CD8+ T-cell Tolerance for Cancer Immunotherapy

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2014 Oct 8

PMID 25290416

Citations 27

Authors

Stephanie R Jackson

Jinyun Yuan

Ryan M Teague

Affiliations

Soon will be listed here.

Abstract

In the final issue of Science in 2013, the American Association of Science recognized progress in the field of cancer immunotherapy as the 'Breakthrough of the Year.' The achievements were actually twofold, owing to the early success of genetically engineered chimeric antigen receptors (CAR) and to the mounting clinical triumphs achieved with checkpoint blockade antibodies. While fundamentally very different, the common thread of these independent strategies is the ability to prevent or overcome mechanisms of CD8(+) T-cell tolerance for improved tumor immunity. Here we discuss how circumventing T-cell tolerance has provided experimental insights that have guided the field of clinical cancer immunotherapy to a place where real breakthroughs can finally be claimed.

Citing Articles

Exploration and validation of a novel reactive oxygen species-related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer.

Li Y, Zhang L, Xu G, Chen J, Zhao K, Li M Front Immunol. 2025; 15:1493528.

PMID: 39749345 PMC: 11693660. DOI: 10.3389/fimmu.2024.1493528.

Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.

de Moraes F, Cavalcanti Souza M, Sano V, Moraes R, Melo A Clin Transl Oncol. 2024; .

PMID: 39154313 DOI: 10.1007/s12094-024-03661-8.

Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts.

Kanikarla Marie P, Sorokin A, Bitner L, Aden R, Lam M, Manyam G Front Oncol. 2022; 12:994333.

PMID: 36212401 PMC: 9532947. DOI: 10.3389/fonc.2022.994333.

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.

Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C Cell Death Discov. 2021; 7(1):136.

PMID: 34091590 PMC: 8179924. DOI: 10.1038/s41420-021-00519-8.

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.

Jiang J, Jin Z, Zhang Y, Peng L, Zhang Y, Zhu Z Front Immunol. 2021; 12:646874.

PMID: 33927719 PMC: 8076602. DOI: 10.3389/fimmu.2021.646874.

References

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Rubinstein M, Kovar M, Purton J, Cho J, Boyman O, Surh C . Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103(24):9166-71. PMC: 1482584. DOI: 10.1073/pnas.0600240103. View

Song D, Ye Q, Carpenito C, Poussin M, Wang L, Ji C . In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011; 71(13):4617-27. PMC: 4140173. DOI: 10.1158/0008-5472.CAN-11-0422. View

Peluso I, Fantini M, Fina D, Caruso R, Boirivant M, Macdonald T . IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007; 178(2):732-9. DOI: 10.4049/jimmunol.178.2.732. View

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel T . Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009; 15(19):6267-76. PMC: 2765061. DOI: 10.1158/1078-0432.CCR-09-1254. View

10.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

11.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

12.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

13.

Furman R, Forero-Torres A, Shustov A, Drachman J . A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 51(2):228-35. DOI: 10.3109/10428190903440946. View

14.

Sabatos C, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng X . Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4(11):1102-10. DOI: 10.1038/ni988. View

15.

Najjar Y, Finke J . Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3:49. PMC: 3597982. DOI: 10.3389/fonc.2013.00049. View

16.

Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S . Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMC: 3866194. DOI: 10.1371/journal.pone.0082742. View

17.

Na S, Hermann A, Sanchez-Ruiz M, Storch A, Deckert M, Hunig T . Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity. 2012; 37(1):134-46. DOI: 10.1016/j.immuni.2012.04.009. View

18.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

19.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

20.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View